Adage Capital Management

Adage Capital Management focuses on managing S&a;P 500 assets predominantly for endowments and foundations.

Business Model:

Revenue: $3.7M

Employees: 11-50

Rankings

Detailed Adage Capital Management Information

Geographic Data

Adage Capital Management headquarters map

Address: 200 Clarendon Street

City: Boston

State: MA

Zip: 02116

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$15B

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&a;P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&a;P index in each of the last 15 years by an average of 3.5%. The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..

Contact Phone:
+16178672800

Contact Email:

Announced Date Company Transaction Money Raised
3/2018 Prevail Therapeutics Series A 75M
11/2020 MedAvail Series E 0
1/2021 Werewolf Therapeutics Series B 0
7/2022 Annexon Biosciences Post-IPO Equity 0
10/2021 Pyramid Biosciences Series B 0
11/2018 Cabaletta Bio Series A 38M
4/2014 Epirus Biopharmaceuticals Series B 36M
12/2012 Ultragenyx Pharmaceutical Series B 75M
10/2018 Tanium Private Equity Round 200M
4/2017 SteadyMed Therapeutics Post-IPO Equity 0
4/2021 Arcellx Series C -
6/2020 C4 Therapeutics Series B 150M
10/2013 Calithera Biosciences Series D 35M
10/2011 Puma Biotechnology Post-IPO Equity 55M
2/2022 Energy Vault Post-IPO Equity 150M
5/2021 SiMa.ai Series B 80M
10/2021 Scout Bio Series B 0
9/2019 GitLab Series E 268M
2/2021 HemoShear Therapeutics Series A 40M
9/2017 Engage Therapeutics Series A 23.6M
4/2014 Vapotherm Series B 0
4/2021 Arch Oncology Series C 0
7/2021 Gopuff Series H 0
8/2020 Pyramid Biosciences Venture Round 0
4/2021 HawkEye 360 Series C 0
12/2022 Karyopharm Therapeutics Post-IPO Equity 0
12/2017 Aptinyx Series B 70M
5/2020 Amplyx Pharmaceuticals Series C 0
5/2020 Pulmonx Equity 66M
5/2021 Larimar Therapeutics Post-IPO Equity 0
6/2018 Precision BioSciences Series B 0
4/2021 Antios Therapeutics Series B 0
4/2014 Nexvet Series B 31.5M
3/2019 Scout Bio Series B 20M
6/2020 Poseida Therapeutics Series D 110M
4/2021 Stem Post-IPO Equity 225M
7/2020 Cerevel Therapeutics Post-IPO Equity 0
2/2020 Flywire Series E 120M
9/2022 Ventyx Biosciences Post-IPO Equity 0
3/2014 Lumena Pharmaceuticals Series B 45M
12/2015 Welldoc Series B 0
9/2018 Galera Therapeutics Series C 70M
2/2021 Silence Therapeutics Post-IPO Equity 0
1/2019 Cabaletta Bio Series B 0
8/2021 Pepgen Venture Round 0
11/2020 Ambrx Private Equity Round 200M
6/2021 ImaginAb Growth 12.8M
6/2015 Advanced Accelerator Applications Venture Round 25.7M
2/2005 FibroGen Venture Round 0
10/2014 MedAvail Series C 0
7/2018 MedAvail Series D 0
5/2021 PathAI Series C 0
3/2013 PTC Therapeutics Private Equity Round 60M
3/2021 Flywire Series F 60M
3/2015 Aimmune Therapeutics Series B 80M
9/2015 AveXis Series D 65M
11/2015 Vapotherm Series C 0
4/2022 Harness Series D 0
12/2018 Annexon Biosciences Series C 75M
3/2019 Prevail Therapeutics Series B 50M
3/2022 Menlo Micro Series C 0
11/2021 Antios Therapeutics Series B 0
3/2015 Collegium Pharmaceutical Private Equity Round 0
5/2021 Forter Series F 300M
6/2021 Goat Group Series F 195M
3/2021 Aura Biosciences Venture Round 0
7/2008 Portola Pharmaceuticals Series C 60.1M
4/2008 Concert Pharmaceuticals Series C 0
7/2015 Protagonist Therapeutics Series C 0
11/2021 HawkEye 360 Series D 0
7/2020 Praxis Precision Medicines Series C 0
3/2021 Caribou Biosciences Series C 115M
7/2015 Vapotherm Series C 0
3/2014 ZS Pharma Series D 0
8/2021 Beckley Psytech Series B 0
11/2015 AppDynamics Series F 0
10/2021 CinCor Pharma Series B 0
9/2020 Eledon Pharmaceuticals Post-IPO Equity 108M
2/2015 Advaxis Post-IPO Equity 0
12/2021 connectRN Venture Round 0
11/2022 BioAtla Post-IPO Equity 0
4/2014 Adverum Biotechnologies Series B 55M
11/2022 Abeona Therapeutics Post-IPO Equity 0
9/2017 ImaginAb Venture Round 0
4/2021 Theseus Pharmaceuticals Series B 0
3/2021 Rapid Micro Biosystems Private Equity Round 0
7/2020 Annexon Biosciences Series C 100M
9/2020 Flame Biosciences Venture Round 100M
7/2022 Annexon Biosciences Post-IPO Equity 0
4/2022 Harness Series D 0
3/2022 Menlo Micro Series C 0
2/2022 Energy Vault Post-IPO Equity 0
12/2021 connectRN Venture Round 0
11/2021 HawkEye 360 Series D 0
11/2021 Antios Therapeutics Series B 0
10/2021 Scout Bio Series B 0
10/2021 Pyramid Biosciences Series B 0
10/2021 CinCor Pharma Series B 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research